Compass Therapeutics (CMPX) Shares Outstanding (Weighted Average) (2023 - 2025)
Historic Shares Outstanding (Weighted Average) for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $168.8 million.
- Compass Therapeutics' Shares Outstanding (Weighted Average) rose 2267.44% to $168.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.8 million, marking a year-over-year increase of 2267.44%. This contributed to the annual value of $137.4 million for FY2024, which is 815.34% up from last year.
- As of Q3 2025, Compass Therapeutics' Shares Outstanding (Weighted Average) stood at $168.8 million, which was up 2267.44% from $138.3 million recorded in Q2 2025.
- Compass Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $168.8 million during Q3 2025, with a 5-year trough of $126.4 million in Q1 2023.
- Over the past 3 years, Compass Therapeutics' median Shares Outstanding (Weighted Average) value was $137.4 million (recorded in 2024), while the average stood at $136.6 million.
- Data for Compass Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY increase of 2267.44% (in 2025) and a maximum YoY decrease of 50.37% (in 2025) over the last 5 years.
- Quarter analysis of 3 years shows Compass Therapeutics' Shares Outstanding (Weighted Average) stood at $127.0 million in 2023, then grew by 8.15% to $137.4 million in 2024, then rose by 22.87% to $168.8 million in 2025.
- Its Shares Outstanding (Weighted Average) stands at $168.8 million for Q3 2025, versus $138.3 million for Q2 2025 and $138.2 million for Q1 2025.